Bayer gets FDA priority review for darolutamide plus docetaxel to treat prostate cancer
Darolutamide is an oral androgen receptor inhibitor (ARi), developed by the company in partnership with Orion Corp, and…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
04 May 22
Darolutamide is an oral androgen receptor inhibitor (ARi), developed by the company in partnership with Orion Corp, and…
02 May 22
The US-based firm sought a variation to the CMA from the European Medicines Agency (EMA) to assess a…
02 May 22
The FDA approval is supported by safety and efficacy findings from the Phase III SELECT-AXIS 2 and Phase…
29 Apr 22
Camzyos is said to be the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source…
29 Apr 22
With the approval, Ultomiris becomes the first and only long-acting C5 complement inhibitor to be approved in the…
28 Apr 22
Vydura is indicated for acute treatment of migraine regardless of aura, and prophylaxis (prevention) of episodic migraine in…
27 Apr 22
The regulatory submission of Pfizer and BioNTech is based on data from the Phase 2/3 clinical study of…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
26 Apr 22
Veklury is indicated for patients who are admitted to the hospital or have a mild-to-moderate disease and are…
26 Apr 22
In the second phase of the alliance, the university will expand its collaboration involvement to include all of…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
25 Apr 22
The company’s decision to withdraw follows consultation with the CHMP, which suggested that the data provided so far…